Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · INSMED Inc (INSM)

Insmed adds Paul Hudson and Utpal Koppikar to its Board of Directors

Neutral Impact 2 of 5 leadership Written later

Insmed appointed two independent directors, Paul Hudson, former CEO of Sanofi, and Utpal Koppikar, CFO of Verily Health, effective October 19, 2026. The filing describes standard director compensation, including an RSU grant with a grant date fair value of approximately $585,000 to each director, and places the new directors on the Compensation and Audit Committees.

Key points

  • Paul Hudson was CEO of Sanofi S.A. from September 2019 through February 2026 and CEO of Novartis Pharmaceuticals from 2016 to 2019; he joins the Compensation Committee.
  • Utpal Koppikar has been CFO of Verily Health Inc. since April 2023 and was EVP and CFO at Atara Biotherapeutics from 2018 to 2023; he joins the Audit Committee.
  • Each director receives an annual cash retainer of $65,000, prorated for 2026, plus an RSU grant of approximately $585,000 that vests in equal parts over three years.
  • The appointments were made by the Board on October 16, 2026, and announced in a press release dated October 20, 2026.

The filing

CompanyINSMED Inc (INSM)
Form8-K, current report
Filed with the SECOct 20, 2026, 7:00 AM ET
Accession number0001140361-26-040177

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.